Business Context and Reporting Period
This Form 8-K is a current report filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on March 14, 2022. The filing discloses the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
The primary material change reported is the appointment of Marwan Noel Sabbagh, M.D., as a Class II director, effective immediately. This appointment fills a vacant directorship until a successor is elected or the director's term expires at the 2024 annual stockholders' meeting.
Guidance, Outlook, and Compensation Details
- Compensation: Dr. Sabbagh is entitled to a $35,000 annual retainer under the Company's Outside Director Compensation Policy.
- Equity Award: On the effective date, Dr. Sabbagh received a nonstatutory stock option for 22,058 shares of Common Stock under the 2019 Equity Incentive Plan.
- Vesting: The options vest in equal annual installments over three years, contingent on continued service.
- Exercise Price: Set at the closing sales price of the Company's common stock on the grant date.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Sabbagh.
Investor Verification Checklist
- Verify the Company's name is Cortexyme, Inc. (CRTX), not Quince Therapeutics, Inc.
- Confirm the total number of outstanding shares to assess the dilution impact of the 22,058 new options.
- Review the Company's Proxy Statement on Schedule 14A (filed April 30, 2021) for full details on the Outside Director Compensation Policy.
- Check the stock price on March 14, 2022, to determine the specific exercise price of the granted options.